AIM ImmunoTech funds immune monitoring study & hires consultant for pancreatic cancer Ampligen trial

AIM ImmunoTech Inc.

Entered $200K grant with Erasmus MC for immune monitoring in pancreatic cancer patients.
Hired Dr. Casper H.J. van Eijck as consultant to recruit European sites for Ampligen pancreatic cancer trials.
Consultant to also introduce COVID, Long COVID & pancreatic cancer studies into Poland.
Consulting fee: up to $2,000/month; aggregate cap of $24,500 after AMP-270 study start.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

AIM ImmunoTech Inc. entered into Unrestricted Grant Agreement with Erasmus University Medical Center (effective 2023-04-04).

Action: entry
Counterparty: Erasmus University Medical Center
Effective: 2023-04-04

Exact text from the filing

On April 4, 2023, AIM ImmunoTech Inc. (the “Company”) executed an Unrestricted Grant Agreement with Erasmus University Medical Center (“EUMC”) pursuant to which EUMC will use its best efforts to diligently carry out immune monitoring in pancreatic cancer patients.

View on SEC.gov

622 material agreements filed in the last 30 days. Browse all material agreements →

AIM ImmunoTech Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-011560

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.